Sareum Holdings Plc · LSE:SAR
Sareum — FY2024 Earnings Presentation
21 slides from Sareum's earnings presentation, Oct 29, 2024
Slide 1: Final Results for the Year Ended 30 June 2024
Final Results for the Year Ended 30 June 2024 29 October 2024 Dr Stephen Parker, Executive Chairman Dr Tim Mitchell, COO & Co-founder Dr John Reader, CSO & Co-founder
Slide 2: Disclaimer
DISCLAIMER The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Company overview
Company overview Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer Strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering Deep expertise in kinase in
Slide 4: Progressing our pipeline
Progressing our pipeline Programme Preclinical Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Potential Indications TYK2 / JAK1 Psoriasis, RA, Lupus, IBD (in-house) Autoimmune disease SDC - 1801 Acute respiratory symptoms of viral infections / Covid-19 Cancer immunotherapy SDC - 1802 Cancer Mono
Slide 5: Highlights from the year
Highlights from the year Proprietary pipeline TYK2 / JAK1 SDC-1801: Autoimmune diseases. Initial focus on psoriasis • Completed a Phase 1 clinical study in Australia, investigating the safety and pharmacokinetics of an oral formulation of programmes SDC-1801 in ascending doses administered to health
Slide 6: TYK2 / JAK1 inhibitor programmes
TYK2 / JAK1 inhibitor programmes Proprietary pipeline
Slide 7: SDC-1801: TYK2/JAK1 Inhibitor for Autoimmune Disorders
SDC-1801: TYK2/JAK1 Inhibitor for Autoimmune Disorders Clinical-stage dual TYK2/JAK1 inhibitor Phase 1 clinical trial completed June 2024. Unblinded data received Q3 2024 High blood exposure achieved. No Serious Adverse Events due to SDC-1801 Adverse event profile similar in treatment and placebo gr
Slide 8: Dual TYK2/JAK1 Inhibition is optimal for suppression of cytokines linked to many autoimmune diseases
Dual TYK2/JAK1 Inhibition is optimal for suppression of cytokines linked to many autoimmune diseases ✓ Potential for broad coverage and increased efficacy across several key autoimmune targets ✓ Greater coverage than TYK2 and JAK1 single inhibitors ✓ Reduced toxicity by not targeting JAK2 ✓ Small mo
Slide 9: Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies
Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies % Patients achieving PASI-75 reduction in psoriasis after 12 weeks Brepocitinib (TYK2/JAK1i) clinical data indicates greater efficacy than deucravacitinib (TYK2i) and/or baricitinib (JAK1/2i) in c
Slide 10: SDC-1801 Human Pharmacokinetic Profile
SDC-1801 Human Pharmacokinetic Profile • Half-life of ~17-20h confirms suitability for once-daily oral dosing • MAD Cohort D – plasma exposure ≈ brepocitinib MAD 100mg QD • Exceeds HWB IFN and IL-12 IC50s throughout dosing period • No haematology or serum creatinine changes observed after 10 days d
Slide 11: Biomarker Data
Biomarker Data • IP-10 (JAK1 / IFNγ signalling) • Dose dependent reductions in IP-10 levels in the MAD cohorts • hsCRP (JAK1 / IL-6 signalling) • Dose dependent reductions in hsCRP levels in the MAD cohorts • IFNα ex-vivo challenge (TYK2/JAK1 signalling) • Dose dependent reductions of pSTAT3+ve and
Slide 12: Differentiation vs brepocitinib
Differentiation vs brepocitinib Brepocitinib clinical dosing is generally at 30mg QD • Increased serum creatinine levels observed at 30mg brepocitinib QD and higher • Due to OCT2 (kidney transporter) inhibition • SDC-1801 has greater selectivity vs OCT2 • SDC-1801 shows no effect on serum creatinine
Slide 13: SDC-1802: Cancer immunotherapy
SDC-1802: Cancer immunotherapy Immunomodulating molecule that has demonstrated good efficacy in preclinical models of cancer • Translational and preclinical studies to be accelerated using funds from recent share subscriptions • Experience in development of SDC-1801 will aid development of SDC-1802
Slide 14: Chk1 Co-development pipeline
Chk1 Co-development pipeline
Slide 15: SRA737: Targeting cancers
SRA737: Targeting cancers Sareum entitled to 27.5% of commercialisation revenues • Originally developed by Sareum in collaboration with several Cancer Research UK-funded organisations • Including current co-development partnership with the Cancer Research Technology Pioneer Fund (CPF) • Successfully
Slide 16: Audited Financial Results
Audited Financial Results For the year ending 30 July 2024
Slide 17: Income statement
Income statement Audited financial results 2024 2023 for the year ended 30 June: £’000 £’000 Revenue - - Administrative expenses (4,596) (4,048) Share of loss of associate (60) (18) Other operating income 22) - Operating loss (4,634) (4,066) Finance income 32) 41) Loss before taxation (4,602) (4,025
Slide 18: Balance sheet
Balance sheet 2024 2023 Audited financial results as at 30 June: £’000 £’000 Non-current assets Property, plant and equipment - 1 Investment in associate 9 46 9 47 Current assets Trade and other receivables 1,299 979 Cash and cash equivalents 1,459 994 2,758 1,973 Current liabilities Trade and other
Slide 19: 2024 - 2025 Anticipated Milestones
2024 - 2025 Anticipated Milestones* Q3 2023 ✓ Q4 2024 Q1 2025 Q2 2025 Data unblinding PK and safety data Clinical Study Report SRA737 update SDC-1801 tox studies Biomarker data SDC-1801 drug product SDC-1802 data *Subject to successful progress 19
Slide 20: SDC-1801: Summary
SDC-1801: Summary Selectivity profile is a differentiator Dual inhibition of TYK2 and JAK1 is expected to provide greater efficacy than agents that inhibit either alone in multiple autoimmune diseases Selectivity for TYK2/JAK1 mitigates non-selective JAK class liabilities related to JAK2 and JAK3 in
Slide 21: Sareum Limited
Sareum Limited Unit 2A, Langford Arch London Road, Pampisford Cambridge CB22 3FX United Kingdom Tel: +44 (0) 1223 497700 Email: info@sareum.com 21